**Checklist for Reporting Human Islet Preparations Used in Research**

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

|  |  |
| --- | --- |
|  | |
| **Manuscript DOI:** https://doi.org/10.2337/DB20-0245 **(**Example, https://doi.org/10.2337/db18-1234) | |
| **Title:** Unbiased profiling of the human proinsulin biosynthetic interaction network reveals a role for peroxiredoxin 4 in proinsulin folding | |
| **Author list:** Duc T. Tran, Anita Pottekat, Saiful A. Mir, Insook Jang, Salvatore Loguercio, Alexandre Rosa Campos, Kathleen M. Scully, Reyhaneh Lahmy, Ming Liu, Peter Arvan, William E. Balch, Randal J. Kaufman, Pamela Itkin-Ansari | |
| **Corresponding author:** Pamela Itkin-Ansari | **Email address:** pitkin@sbpdiscovery.org |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Islet preparation** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8a** |
| **MANDATORY INFORMATION** | | | | | | | | |
| Unique identifier | HP-16020-01 | HP-16007-01 | HP-15338-01 | HP-15315-01 | HP-15259-01 | HP-15232-01 | HP-15157-01 | HP-19038-01 |
| Donor age (years) | 57 | 56 | 41 | 51 | 37 | 36 | 27 | 55 |
| Donor sex (M/F) | F | F | M | F | M | F | M | M |
| Donor BMI (kg/m2) | 23.1 | 23.1 | 24.6 | 21.0 | 25.4 | 24.6 | 18.3 | 28.1 |
| Donor HbA1c or other measure of blood glucose control | 5.0% | 5.4% | 5.4% | 5.3% | 5.5% | 4.8% | 5.8% | 5.0% |
| Origin/source of isletsb | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs |
| Islet isolation centre | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs | Prodo Labs |
| Donor history of diabetes? Yes/No | No | No | No | No | No | No | No | No |
| **If Yes, complete the next two lines if this information is available** | | | | | | | | |
| Diabetes duration (years) |  |  |  |  |  |  |  |  |
| Glucose-lowering therapy at time of deathc |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **RECOMMENDED INFORMATION** | | | | | | | | |
| Donor cause of death | stroke | stroke | stroke | stroke | stroke | stroke | Head trauma | stroke |
| Warm ischaemia time (h) |  |  |  |  |  |  |  |  |
| Cold ischaemia time (h) |  |  |  |  |  |  |  |  |
| Estimated purity (%) |  |  |  |  |  |  |  |  |
| Estimated viability (%) |  |  |  |  |  |  |  |  |
| Total culture time (h)d |  |  |  |  |  |  |  |  |
| Glucose-stimulated insulin secretion or other functional measuremente |  |  |  |  |  |  |  |  |
| Handpicked to purity? Yes/No |  |  |  |  |  |  |  |  |
| Additional notes |  |  |  |  |  |  |  |  |

aIf you have used more than eight islet preparations, please complete additional forms as necessary

bFor example, IIDP, ECIT, Alberta IsletCore

cPlease specify the therapy/therapies

dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results